Introduction
RASSF1A is one of the recently identified tumor suppressor genes (Dammann et al., 2000) . It resides on chromosome 3p21.3, a region that frequently undergoes homozygous or heterozygous deletions in many human malignancies (Dammann et al., 2000 (Dammann et al., , 2001b . Loss of heterozygosity (LOH) at chromosomal region 3p21.3 occurs frequently in lung, breast, nasopharyngeal, ovarian and renal cancers (Whang-Peng et al., 1982; Kok et al., 1997; Wistuba et al., 2000; Maitra et al., 2001) . Many recent studies have demonstrated that epigenetic inactivation of RASSF1A, involving hypermethylation of the CpG island in its promoter, is also extremely common in many human tumors (Dammann et al., 2000; Agathanggelou et al., 2001; Burbee et al., 2001; Byun et al., 2001; Dammann et al., 2001a, b; Dreijerink et al., 2001; Lee et al., 2001; Lo et al., 2001; Morrissey et al., 2001) . RASSF1A promoter hypermethylation, resulting in promoter silencing concomitant with absent mRNA, has been found in 40% of non-small-cell lung tumors (NSCL) and more than 80% of the smallcell lung primary tumors or cell lines (Dammann et al., 2000; Burbee et al., 2001; Dammann et al., 2001a, b) . Similarly, 60% of gastric tumors ), 40% of ovarian tumors Yoon et al., 2001) , 56% of renal tumors (Dreijerink et al., 2001; Yoon et al., 2001 ) and 62% of bladder tumors have been found to have lost RASSF1A mRNA expression . Treatment with demethylating agent 5-aza-2 0 -deoxycytidine in RASSF1A-nonexpressing cells induces the re-expression of RASSF1A mRNA transcripts further confirming the epigenetic mechanisms of its silencing (Dammann et al., 2000; Byun et al., 2001; Dammann et al., 2001b; Dreijerink et al., 2001; Lee et al., 2001; Lo et al., 2001) . That RASSF1A functions as tumor suppressor was further supported by the findings that expression of exogenous RASSF1A in nonexpressing tumor cells (i) reduces colony formation and (ii) inhibits anchorage-independent growth on soft-agar and tumor formation in nude mice (Dammann et al., 2000) . Although these studies have demonstrated that RASS-F1A is a potentially important tumor suppressor gene whose inactivation may play a critical role in tumor development, very little is known about the mechanism(s) by which the RASSF1A tumor suppressor impacts cell growth regulation.
Recent studies have demonstrated that regulation of microtubule stability is one of the key events that control cell growth (Oliferenko and Balasubramanian, 2002; Shimoda and Solomon, 2002; Tanaka, 2002) . Microtubules are highly dynamic cytoskeletal structures that are assembled by the polymerization of a-and btubulins (Albert et al., 2002) . Microtubule assembly or disassembly is tightly controlled during various phases of the cell cycle. For example, the cytosolic microtubules undergo a rapid disassembly during mitosis such that the tubulin subunits reassemble to build the spindleshaped apparatus called mitotic spindle (Cassimeris, 1999; Lodish et al., 2000; Nogales, 2001; Albert et al., 2002) . During this process, microtubules undergo a phase of rapid lengthening and shorting to capture chromosomes at the kinetochore and partition the sister chromatid equally in two dividing cells. The mitoticspindle checkpoint (Rudner and Murray, 1996; Amon, 1999; Cassimeris, 1999; Schuyler and Pellman, 2001; Albert et al., 2002) is important in that it ensures the precise arrangement and alignment of chromosomes prior to equal separation of sister chromatids to the newly divided cells (Rudner and Murray, 1996; Amon, 1999; Cassimeris, 1999; Schuyler and Pellman, 2001; Albert et al., 2002) . Such processes are important in regulating cell cycle and maintaining genome stability (Cassimeris, 1999; Lodish et al., 2000; Albert et al., 2002) and thus, proteins that impact microtubule stability are likely to affect cell cycle controls and genome stability.
Several microtubule-binding proteins have been identified that regulate microtubule formation and stabilization (Cassimeris, 1999; Lodish et al., 2000; Nogales, 2001; Albert et al., 2002) . Microtubule-associated proteins (MAPs), such as tau, microtubule-associated protein-2 (MAP2) and microtubule associated protein-4 (MAP4), promote microtubule assembly and stabilization, and cause microtubule bundling (Cassimeris, 1999; Lodish et al., 2000; Nogales, 2001; Albert et al., 2002) . Recently, the adenomatous polyposis coli (APC) protein, an important tumor suppressor responsible for familial and sporadic colon cancer (reviewed in Kinzler and Vogelstein, 1996; Berrueta et al., 1998; MimoriKiyosue and Tsukita, 2001) , has also been identified as a microtubule-interacting protein (Smith et al., 1994; Kaplan et al., 2001; Nakamura et al., 2001; Bienz, 2002; Mogensen et al., 2002) . APC directly binds to microtubule via its carboxyl terminus basic region (Deka et al., 1998; Askham et al., 2000; Bienz, 2002) and deletion of microtubule-binding site from the Cterminal domain of APC significantly decreases its ability to stabilize microtubules (Deka et al., 1998; Bienz, 2002) . APC has also been suggested to function in the kinetochore-microtubule attachment as well as in chromosomal segregation during mitosis (Kaplan et al., 2001) . Deletions in APC gene are common in human colorectal cancers, which may eliminate the microtubule-binding potential of APC and thus contribute to chromosomal instability in cancer cells (Smith et al., 1994; Kaplan et al., 2001; Mimori-Kiyosue and Tsukita, 2001; Bienz, 2002) . In the present study, we show that RASSF1A tumor suppressor protein is a microtubuleinteracting protein that stabilizes microtubules and induces G 1 , G 2 /M arrest.
Results
Expression of exogenous RASSF1A inhibits colony formation in human cancer cells Figure 1a shows that the RASSF1A mRNA expression is either absent or reduced in various human cancer cell lines. To evaluate the RASSF1A expression at the protein levels, we performed Western blot analysis using anti-RASSF1A antibodies and found that indeed, RASSF1A protein expression correlates well with its mRNA expression (Figure 1b, upper panel) . That the RASSF1A-specific protein was not detected in the lysates of RASSF1A-nonexpressing cells (MCF-7, Figure 1 (a) Differential expression of RASF1A mRNA in human cancer cell lines. The expression of RASSF1A mRNA was detected by the standard reverse-transcribed (RT)-PCR methods using the RASSF1A isoform-specific PCR primers (Burbee et al., 2001) , and the b-actin primers were also used as internal control to evaluate the amount of input as well as the integrity of the mRNA. As shown, the expression of the RASSF1A mRNA is undetectable in MCF-7, 293T, A549 and MDA231 cells. (b) Expression of endogenous RASSF1A protein in human and mouse cell lines. Upper panel shows the expression of endogenous RASSF1A protein that was detected by the Western blotting using a RASSF1A isoform-specific rabbit polyclonal antibody. It is of note that the expression of RASSF1A protein is not detectable in MCF-7, 293T and A549 cells. Lower panel shows the specificity of the RASSF1A antibodies demonstrated by competition with RASSF1A-specific peptides. Immunoblotting was performed on duplicated membranes using polyclonal RASSF1A antibodies. For RASSF1A peptide competition, RASSF1A antibodies were preincubated with RASSF1A-specific peptide for 2 h prior to using in the immunoblotting on the peptide membrane. (c) Exogenous expression of RASSF1A inhibits colony formation by colon (HCT116) and breast (MCF-7) cancer cells. Cells were transfected with equimolar concentration of pCEP4 empty vector (Vector) or pCEP4-Myc-RASSF1A expression vector (RASSF1A) using Lipofectamine 2000 transfection reagents (Life Technology). Cells were subsequently selected for hygromycin resistance for 14-20 days and stained with crystal violet. Figure 1b lower panels) competed with endogenous RASSF1A protein, thereby confirming the specificity of these antibodies. To examine the tumor suppressive potential of RASSF1A, we selected MCF-7 and HCT116 cell lines that exhibit either low or absent expression of RASS-F1A (Figure 1a and b) . MCF-7 and HCT116 cells were transfected with equimolar concentrations of control empty vector or the Myc-tagged RASSF1A expression vector to test the effect of exogenous RASSF1A on their growth by the colony formation assay. Representative photographs of the tissue culture plates depicting colony formation in vector or RASSF1A-transfected cells are shown in Figure 1c . As is shown, the introduction of exogenous RASSF1A reduced colony formation in both MCF-7 and HCT116 cell lines (Figure 1c ). We also found that the expression of exogenous RASSF1A had no effect on the colony formation by Hela cells (data not shown), which exhibit higher levels of RASSF1A mRNA and protein expression (Figure 1a and b) . Western blot analysis with anti-Myc antibody confirmed the expression of Myc-tagged RASSF1A protein (Figure 1d ). Quantitative results depicting the growth inhibitory potential of exogenous RASSF1A in HCT116 and MCF-7 cells are summarized in Table 1 .
RASSF1A colocalizes with microtubules in the interphase cells
We generated an expression construct carrying the GFPtagged RASSF1A to monitor the subcellular localization of RASSF1A. NIH3T3 cells were transiently transfected with expression vectors carrying GFP-alone or GFP-tagged RASSF1A and analysed under a fluorescent microscope. As shown in Figure 2 , the GFP-alone and GFP-RASSF1A-expressing cells exhibited very different expression patterns. GFP-alone was diffusely distributed throughout the cells including the nuclei. The GFP-RASSF1A, by contrast, largely localized in the cytoplasm; and its staining did not colocalize with DAPI that stains nuclei, indicating that RASSF1A was not expressed in the nucleus. Importantly, we found that the staining pattern of GFP-RASSF1A appeared similar to that of microtubules. We, therefore, designed further experiments to examine whether RASSF1A colocalizes with microtubules. To this end, we transiently transfected GFP-alone or GFP-RASSF1A constructs into NIH3T3 cells, and performed immunostaining using an anti-a-tubulin primary antibody followed by a rhodamine-conjugated anti-mouse secondary antibody. As shown in Figure 2A , the network-and fiber-like staining pattern of RASSF1A (e; green color) largely overlapped with that of a-tubulin (f and h; red color); clearly indicating that GFP-RASSF1A colocalized with the microtubules in the RASSF1A-expressing cells. Furthermore, the fibers of microtubules mostly appeared thickened and formed bundles. This type of RASSF1A expression pattern was not restricted to the NIH3T3 cells but was also noted in four other cell lines including A549, MCF-7, HCT116 and HeLa (data not shown). Our data thus suggest that RASSF1A is a microtubule-associated protein that may also induce stabilization and bundling of microtubules.
RASSF1A colocalizes with microtubules in the mitotic spindles
To further assess the association of RASSF1A with microtubules, we first performed experiments to examine whether RASSF1A cosegregates with microtubules in taxol-treated cells. Taxol is an anticancer drug that binds to and stabilizes microtubules and thereby gives rise to abnormal mitotic spindle formation and M-phase growth arrest (reviewed in Downing, 2000) . Cells (NIH3T3 and MCF-7) were transiently transfected with either GFP or GFP-RASSF1A constructs for overnight and treated with taxol. Immunostaining using anti-atubulin antibody was also performed to correlate the expression pattern of a-tubulin with RASSF1A. As shown in Figure 2B , RASSF1A in taxol-treated cells clearly cosegregated with microtubules. Our results thus demonstrate that RASSF1A does interact with microtubules in the interphase cells ( Figure 2A ) as well as in taxol-treated mitotic arrested cells ( Figure 2B ).
Next, we investigated whether RASSF1A indeed associates with microtubules during mitotic spindle formation under physiological conditions, that is, cells entering into mitosis naturally without interference with microtubule-arresting agents. To this end, we examined several cell lines including MCF-7, HCT116, A549 and 293T for the evidence of RASSF1A-microtubule Figure 2c demonstrates that, indeed, RASSF1A colocalized with microtubules in mitotic spindle during mitosis, and strong staining of RASSF1A was noted at and near the regions corresponding to the microtubule-organizing center (MTOC). It is possible that interaction with microtubules could be an important event for the biological effects of this novel tumor suppressor. It is of note in this context that several other mitotic spindleassociated proteins are known to play an important role in regulating cell cycle via their interactions with microtubules at the mitotic spindles (Rudner and Murray, 1996; Amon, 1999; Cassimeris, 1999; Approximately 24 h after transfection, cells were fixed with 1% paraformaldehyde for 1 h followed by cold methanol at À201C for 10 min. Cells were labeled with a-tubulin primary antibody (1 : 500, Sigma Chemicals St Louis, MO, USA), followed by a rhodamine-conjugated secondary antibody. DNA was counterstained with DAPI nuclear dye as we have previously described . It is of note that strong GFP-RASSF1A staining appears at and near the microtubule-organizing center (MTOC) at two poles. i-m, images from a cell in late prophase. At this stage, strongest staining of RASSF1A is noted at a region that contacts with chromosomes. K is a two-color (red and green) merge image of i and j, whereas m is a three-color (red, green and blue) merge image of i, j and l. Arrows in c, g and l point to the condensed chromatin during mitosis Lodish et al., 2000; Schuyler and Pellman, 2001; Albert et al., 2002) .
RASSF1A interactions with microtubules demonstrated by cosedimentation assay
To further demonstrate that RASSF1A interacts with microtubules in vivo, we performed microtubule cosedimentation assay (Goedert et al., 1996; Goode et al., 2000; Reese and Haimo, 2000; Walenta et al., 2001) . The 293T cells were transiently transfected with either GFPalone or GFP-RASSF1A fusion construct. At 24 h after transfection, cells were lysed and the standard microtubule cosedimentation assay was performed as described in Material and methods. Cell lysates containing approximately equal amounts of GFP or GFP-RASS-F1A fusion protein from each transfectans were then incubated with taxol in the presence of GTP to stabilize microtubules. After incubation, the reaction mixtures were subjected to high speed centrifugation as described (Goedert et al., 1996; Goode et al., 2000; Reese and Haimo, 2000; Walenta et al., 2001) , and supernatants and pellets were collected and analysed by Western blotting using anti-GFP or anti-a-tubulin antibodies. In this assay, protein that potentially associates with microtubules should be captured in the pellet fraction with microtubules. As shown in Figure 3 , under these conditions, the GFP protein alone was not detected in the pellet sediment (P) (Figure 3a , upper panel, lane 3); whereas abundant amount of GFP-alone was clearly Endogenous RASSF1A protein also interacts with microtubules Next, we investigated whether endogenous RASSF1A also interacts with microtubules. To this end, we utilized anti-RASSF1A antibodies to perform co-immunoprecipitation assays. Owing to the nature of these experiments, MEF cells that express relatively higher levels of , were included as negative controls. Cells growing in 100 mm plates were lysed and total cell lysates were incubated either with anti-a-tubulin antibodies or equal amounts of control mouse IgG. The immunoprecipitates that were collected by magnetic protein G beads (no centrifugation was involved) were analysed by Western blotting using RASSF1A-specific antibodies. As shown in Figure 3c , endogenous RASS-F1A protein co-precipitate with a-tubulin indicating that endogenous RASSF1A interacts with microtubules.
No such interactions were detected in 293T cells which do not express the endogenous RASSF1A protein or in MEFs lysate incubated with IgG ( Figure 3c ). The anti-RASSF1A antibodies were also used to detect the interactions between microtubules and GFP-tagged RASSF1A protein by co-immunoprecipitation assays and similar interactions between a-tubulin and GFP-RASSF1A were observed (data not shown). Thus, these biochemical data coupled with our florescent microscopic results demonstrate that RASSF1A tumor suppressor is a novel microtubule-associated protein.
RASSF1A stabilizes microtubules
Results presented above indicate that RASSF1A associates with microtubules. Next, we investigated whether RASSF1A would also stabilize microtubules. We have observed in several cell lines that expression of GFP-RASSF1A caused structural changes in the microtubules such that the microtubule fibers became thickened and formed bundles ( Figure 2A ). To further determine whether RASSF1A can stabilize microtubules, several sets of experiments were performed. First, we compared the structure of microtubules in GFP-or GFP-RASS-F1A-expressing cells in the presence or absence of nocodazole, a microtubule-specific agent that binds to the subunits of microtubules and prevents their polymerization (Downing, 2000; Lodish et al., 2000; Albert et al., 2002) . Treatment with nocodazole caused dispersal of microtubules in GFP-alone-transfected (Figure 4a , b) or nontransfected cells (Figure 4a , f and j, cells not pointed by arrows). However, in RASSF1A-expressing cells, microtubules still maintained the network-like structure ( Figure 4A , e-h and i-l, arrows), and as can be noted by the thickened appearance of the microtubules in the RASSF1A-transfected cells, nocodazole treatment did not alter RASSF1A's bundling effect on microtubules ( Figure 4A , f and j, arrows). These results suggest that RASSF1A is a microtubulestabilizing protein. Next, we used one additional approach to confirm this finding. Cold temperature is known to prevent microtubule polymerization (Bosc et al., 1996; Lodish et al., 2000; Albert et al., 2002) . We found that exposure of cells to ice-cold temperature had similar effect on microtubules that was noted with nocodazole. As shown in Figure 4B , microtubules were dispersed by cold temperature in cells not expressing RASSF1A ( Figure 4B , b and f, cells not pointed by arrows). However, expression of RASSF1A maintained the network-like structure of microtubules, which was not seen in nontransfected cells immediately adjacent to the RASSF1A transfectants ( Figure 4B , a to h, cells pointed by arrows). These results thus demonstrate that RASSF1A is a microtubule-binding and stabilizing protein.
RASSF1A interacts with microtubules via a region residing at amino acid 120-288
Previous studies have shown that most of the known microtubule-associated proteins contain a positively charged basic domain, which can bind directly to the acidic tails of tubulins (Irminger-Finger et al., 1990; Gustke et al., 1994; Bienz, 2002) . The amino-acid At 24 h after transfection, cells were lysed and microtubule cosedimentation assay was performed as described in Material and methods. Briefly, total cell lysates from transfectants were incubated with taxol (80 mM) in the presence of GTP. The samples were then spun through a cushion buffer containing 40% glycerol at 100 000 g for 45 min. Total protein lysate (L), supernatant (S) and pellet (P) were immunoblotted with anti-GFP or anti-a-tubulin antibodies. These data demonstrate that RASSF1A binds to microtubules in vivo. (c) Co-immunoprecipitation of endogenous RASSF1A and a-tubulin. Cell lysates were prepared from MEF or 293T cells as described in Material and methods. In total, 1 mg of respective total cell lysate was incubated with taxol and GTP for stabilization of microtubules. The cell lystates were then preincubated with mouse monoclonal anti-a tubulin antibody or equal amount of control normal mouse IgG. The antibody-protein complexes were immobilized on Dynal protein G magnetic beads and the bead-bound proteins were subjected to Western blotting using anti-RASSF1A antibodies sequence analysis of RASSF1A reveals the presence of a stretch of 94 amino acids at the middle of the RASSF1A protein that is highly basic (Figure 5a ). We hypothesize that this highly charged basic region of RASSF1A could be involved in RASSF1A and microtubule interactions.
To test this hypothesis, we generated a set of GFPtagged RASSF1A deletion constructs (Figure 5b ), in which regions containing the previously predicted functional domains as well as the basic region were deleted by site-directed mutagenesis. Expression of the deleted versions of RASSF1A was confirmed by Western blotting using anti-GFP antibody (Figure 5c ). The localizations of these wild-type-or deleted forms of GFP-tagged RASSF1A were analysed under fluorescent Figure 4 (a) RASSF1A stabilizes microtubules in the presence of nocodazole. MCF-7 cells growing on Lab-tek slide chambers were transiently transfected with expression vector carrying GFP cDNA or GFP-RASSF1A fusion construct. Approximately 24 h after transfection, cells were treated with nocodozole (20 mg/ml) for 30 min and fixed with 1% paraformaldehyde followed by cold methanol as described in Materials and methods. Cells were labeled with a-tubulin and DAPI nuclear dye as described in Figure 2 . a-d, cells were transfected with GFP-alone vector. e-l, cells were transfected with GFP-RASSF1A fusion construct. In these specimens, cells transfected with RASSF1A are indicated by arrows. It is of note that only in cells that were transfected with RASSF1A, the microtubules still maintain a network-like structure. Microtubules in GFP-alone (a-d) or nontransfected cells (not pointed by arrows) that are immediately adjacent to the RASSF1A transfectants (arrows, e to l) are diffuse and evenly distributed in cytosol. (b) RASSF1A stabilizes microtubules in cells exposed to cold temperature. MCF-7 cells were transfected as described in (a). At 24 h after transfection, cells growing on Lab-tek slide chambers were shocked with cold temperature for 1 h and then fixed as described in (a) Note that, in the same specimens, only in RASSF1A-transfected (arrows) cells, microtubules still maintain the network-like structure.
In the nontransfected cells (not pointed by arrows) that are immediately adjacent to RASSF1A-transfected cells (arrows), microtubules are diffuse and evenly distributed in cytosol RASSF1A interacts with microtubules and induces cell cycle arrest R Rong et al microscope. As shown in Figure 6 , the two deleted versions of RASSF1A, that is, D165-200 and D201-258 that lack the N-terminal or the C-terminal part of the basic region do not exhibit microtubule-specific staining pattern. The expression patterns of these deletion variants was no longer network-and fiberlike, but rather punctate in appearance throughout the cytosol ( Figure 6 ). Two additional deletion variants of RASSF1A, that is, D120-164 and D259-288 that lack the sequences flanking the N-termianl or C-terminal part of the basic region, also do not display microtubule-associated subcellular distribution pattern. By contrast the deletion mutants, D1-50 and D51-119, that lack the N-terminal regions of the RASSF1A protein but retain the basic region exhibit microtubuleassociated subcellular distribution similar to that of the wild-type protein (Figures 5b and 6 ). Similarly the deletion variant, D289-340, that lacks the 51 aminoacid-long C-terminal region but retains the basic region also exhibits microtubule-associated subcellular distribution similar to that of the wild-type protein (Figures 5b and 6 ). We also found that both the Nterminal and C-terminal regions of the RASSF1A protein may not be involved in microtubules stabilization since the N-and C-terminal deletion mutants D1-50, D51-119 and D289-340 still promote microtubule bundling and maintain the microtubule stabilizing effects against nocodazole-induced microtubule dispersal (Figure 7 , arrows). Taken together, these results suggest that the region corresponding to amino acids 120-288 of the RASSF1A protein is essential for its interaction with the microtubules and the same region is likely to be involved in its ability to stabilize microtubules. RASSF1A induces cell cycle arrest in both G 1 and G 2 /M phases Our observation that RASSF1A associates with and stabilizes microtubule prompted us to examine the role of RASSF1A on cell cycle progression. We analysed MCF-7 and 293T cells for RASSF1A's effect on cell cycle progression. Cells were transiently transfected with GFP-alone or GFP-RASSF1A expression vectors and fixed 24, 48 and 72 h post-transfection. Cell cycle progression was determined by fluorescence-activated cell sorter (FACS) analysis and the GFP-RASSF1A-expressing cells were compared to the GFP-aloneexpressing cells. Representative results of these experiments are shown in Table 2 . As is shown, MCF-7 cells expressing RASSF1A exhibit G 1 arrest 24 h following transfection (compare 55% in GFP-alone cells to 81% in RASSF1A-expressing cells) and this G 1 arrest was sustained until 48 h post-transfection (65 vs 83%, Table 2 ). This observation that RASSF1A induces G 1 growth arrest is consistent with recent reports suggesting that exogenous RASSF1A induces G 1 arrest in H1299 human cancer cells (Shivakumar et al., 2002) . Our new findings in the current studies, however, indicate that (i) the RASSF1A-induced G 1 arrest appears to be transient and (ii) RASSF1A also induces G 2 /M arrest. As shown in Table 2 , 72 h post-transfection, the number of RASSF1A-expressing cells in G 1 dropped to that noted in GFP-alone-expressing MCF-7 cells, but there was a concomitant increase in the population of RASSF1A- Figure 6 Subcellular localization of GFP-tagged RASSF1A deletions. HCT116 colon cancer cells were transiently transfected with constructs carrying the GFP-tagged wild-type RASSF1A or the deleted variant. Approximately 24 h after transfection, cells were fixed and stained with anti-a-tubulin and DAPI as described in Figure 2 . The deletions D1-50, D51-119 and D289-340 maintained the network-and fiber-like staining pattern of full-length RASSF1A. These three deletions also colocalize with microtubules as seen in the merged images. It is of note that deletions D120-164, D165-200, D201-258 and D259-288 exhibit punctuated localization patterns, which do not colocalize with the microtubule staining. GFP-RASSF1A-transfected cells are indicated by arrows RASSF1A interacts with microtubules and induces cell cycle arrest R Rong et al expressing cells in G 2 /M. We also noted increasing number of RASSF1A-expressing cells in the sub-G 0 / G 1 phase, which represents an apoptotic fraction (from 1.5% at the 24 h to 17% at 72 h). In GFP-aloneexpressing MCF-7 cells, however, the percentage of sub-G 0 /G 1 cells (apoptotic fraction) remained relatively constant. Unlike in MCF-7 cells, RASSF1A did not induce G 1 arrest in 293T cells, but rather a more pronounced G 2 /M arrest was noted. In all, 40% of RASSF1A-expressing cells were in G 2 /M phase by 72 h compared to that of 11% in GFP-alone-expressing cells (Table 2) . Interestingly, an increase in sub-G 0 /G 1 population was not observed in 293T cells transfected with RASSF1A (Table 2 ). The expression of the GFPtagged RASSF1A protein was confirmed by Western blotting (Figure 8a ). Thus, our results demonstrate that RASSF1A not only induces G 1 arrest but also the G 2 /M growth arrest. It could be argued that RASSF1A-mediated G 1 and G 2 /M arrest result due to nonphysiologic levels of exogenous RASSF1A. To further explore this possibility, we analysed the expression level of exogenous GFP-RASSF1A expressed in 293T cells with that of endogenous RASF1A in MEFs. MEFs were selected for comparison since they are normal cells and among all cell lines tested, they exhibit the highest levels of endogenous RASSF1A protein ( Figure 1b) . As shown in Figure 8b , expression level of the exogenous GFP-RASSF1A expressed in 293T cells (under conditions MCF7 and 293T cells, seeded in 100 mm plates at 40-50% confluency, were transfected with 10 mg of plasmids expressing either GFP-alone or GFP-RASSF1A. At 24, 48 and 72 h after transfection, cells were trypsinized, washed and fixed with 2% paraformaldehyde for 1 h. Cells were then washed in 1 Â PBS, incubated with 70% ethanol treated with RNase followed by staining with propidium iodide. Cell cycle phase distributions were determined by analysing the DNA content of GFP (green fluorescent protein)-expressing cells using flow cytometry. Numbers represent the means of three independent experiments used for cell cycle analysis) is comparable to that of the endogenous RASSF1A in normal MEF cells. We should, however, point out that although GFP-RASS-F1A levels in the transiently transfected cells is comparable to the endogenous levels of RASSF1A in MEFs, we cannot rule the possibility of variable levels of GFP-RASSFA1 among the individual transfected cells. Therefore, it is formally possible that the individual cells may exhibit variable response to different levels of exogenous RASSF1A.
The basic domain-containing RASSF1C also interacts with and stabilizes microtubule and induces G 2 /M arrest RASSF1 gene encodes several isoforms but the transcripts of isoforms RASSF1A and RASSF1C are predominatly detected in a majority of the normal human tissues; the other RASSF1 variants exhibit a tissue-specific expression pattern (Dammann et al., 2000; Burbee et al., 2001) . The RASSF1A and C isoforms are divergent at their N-termini due to alterative transcription initiation but identical at the basic regions and C-termini (Dammann et al., 2000; Burbee et al., 2001) . We sought to investigate whether the isoform C, which also contains the basic region, could interact with the microtubules and affect G 2 / M phase of cell cycle. The 293T cells were transfected with GFP expression vector and GFP-tagged RASSF1C. Our results presented in Figure 9 indicate that RASSF1C also interacts with and stabilizes microtubules (Figure 9a and b) . Table 3 shows that expression of exogenous GFP-tagged RASSF1C induces Comparison of the levels of endogenous RASSF1A with exogenously expressed GFP-tagged RASSF1A. Equal amounts of total protein lysates from untransfected MEF, Hela, HCT116 or GFP-RASSF1A-transfected 293T cells were analysed for the expression of RASSF1A protein by Western blotting using anti-RASSF1A antibody. The same membrane was stripped and reblotted with anti-a tubulin antibody. Endo: endogenous RASS-F1A; Exo: exogenous GFP-RASSF1A. The GFP-RASSF1A was also detected on the same membrane but due to its higher molecular mass, it is shown in proximity to endogenous RASSF1A Experiments were performed as described in the legend to Table 2 . Numbers represent the means of three independent experiments G 2 /M cell cycle arrest, a finding similar to that noted in RASSF1A-expressing cells.
Discussion
We have presented several lines of morphological and biochemical evidence, which support our conclusion that RASSF1A interacts with and stabilizes microtubules. (i) We show that exogenously expressed GFP-RASSF1A colocalizes with microtubules in the interphase and mitotic cells. The network-and fiber-like staining pattern of GFP-RASSF1A largely overlaps with that of a-tubulin in the RASSF1A-expressing interphase cells (Figure 2A) . In spontaneous or druginduced mitotic cells, RASSF1A was found to colocalize with microtubules in the mitotic spindle ( Figure 2B and C).
(ii) Using the microtubule cosedimention assay and immunoprecipitation, we also provide biochemical evidence that RASSF1A protein interacts with microtubules ( Figure 3 ). The interactions between RASSF1A and microtubules appear specific and have physiological relevance since the interactions were observed for both exogenous and endogenous RASSF1A by using different methods. (iii) RASSF1A expression and interactions with microtubules prevented the nocodazole or cold temperature-induced microtubule dispersal (depolymerization), indicating that RASSF1A appears to facilitate microtubule stabilization against dissociation of the tubulin subunits caused by nocodazole and cold temperature. (iv) We have also identified a region that harbors a basic domain as a potential microtubule-binding region of RASSF1A. Various deletions of this region affected the abilities of RASS-F1A to interact with microtubules. Together, our findings support the notion that RASSF1A is a novel microtubule-binding protein that serves to stabilize this cytoskeletal structure. Our present study also reveals that RASSF1A is a potentially important cell cycle regulator. For example, expression of exogenous RASSF1A induced G 1 arrest, a finding that is consistent with recent reports suggesting that exogenous RASSF1A induces G 1 arrest (Shivakumar et al., 2002) . As reported recently, one potential mechanism by which RASSF1A induces G 1 growth arrest could be the ability of this protein to inhibit cyclin D1 protein accumulation in RASSF1A-expressing cells (Shivakumar et al., 2002) . In the present study, we further report our novel findings that RASSF1A-induced G 1 arrest is transient, and that RASSF1A also induces G 2 /M arrest. For example, by 72 h, the proportion of RASSF1A-expressing G 1 -arrested cells was significantly reduced to that noted in GFP-alone-expressing MCF-7 cells, but there was a concomitant increase in the population of RASSF1A-expressing cells in G 2 /M.
In the case of 293T cells, RASSF1A induced only G 2 / M arrest but not G 1 arrest. The 293T cells are known to carry the adenovirus and SV40 virus large T antigen (Graham et al., 1977) . Both of these proteins are known to inactivate the Rb tumor suppressor by binding to Rb pocket region and consequently abolish Rb-mediated cell cycle regulation in G 1 (Ludlow et al., 1990; Bandara and La Thangue, 1991) . Shivakumar et al. (2002) recently reported that RASSF1A-mediated G 1 arrest was associated with a reduced accumulation of cyclin D1, and those effects were reversed by events that abrogate Rb-mediated cell cycle control either directly (via ectopic expression of the papillomavirus E7 viral protein) or indirectly (via overexpression of cyclin D1). It is therefore possible that the lack of G 1 arrest in 293T cells could result due the presence of E1A and the large T antigen that inactivate Rb in these cells. Future studies will further examine how RASSF1A may modulate the Rb activity in G 1 cell cycle control.
RASSF1A-induced G 2 /M arrest was more pronounced in 293T cells as compared to MCF-7 cells (Table 2 ). In MCF-7 cells (but not in 293T cells), the transient G 1 arrest may have prevented cell cycle progression into the G 2 /M phase at an early time point when no G 2 /M arrest was observed. The G 2 /M arrest becomes more pronounced by 72 h-post transfection when G 1 arrest was released (Table 2) . Our results thus indicate that cell cycle regulation at G 1 and G 2 /M phases appears to be important in RASSF1A-mediated growth suppression. It is of note that RASSF1A induces G 2 /M arrest in both MCF-7 and 293T cells, whereas RASS-F1A-mediated G 1 arrest is noted in MCF-7 cells but not in 293T cells. These findings thus argue against the possibility that RASSF1A-induced G 2 /M arrest in MCF-7 cells is simply a result of delayed cell cycle progression from G 1 arrest. Instead, our data suggest that RASSF1A may modulate the G 1 and G 2 /M cell cycle regulation via two independent mechanisms.
We have also identified a region at amino-acid positions 120-280 on RASSF1A protein that is responsible for the RASSF1A and microtubule interactions. This region harbors a series of basic residues and deletion of this region abolished RASSF1A interactions with microtubules. Of note, RASSF1C, another isoform of RASSF1, that contains this basic region also interacts with microtubules. Like RASSF1A, the C isoform can stabilize microtubules against microtubule-destabilizing agent nocodozol and induce cell cycle arrest at G 2 /M phase. While this manuscript was being reviewed, Song et al. (2004) reported that RASSF1A interacts with microtubules, and that RASSF1A interacts with a mitotic regulator Cdc20. The authors proposed that the RASSF1A/Cdc20 interactions inhibit the formation of APC/C (anaphase-promoting complex/Cdc20) complex and induce mitotic arrest. Our results are in agreement with those reported by Song et al. (2004) that RASSF1A is indeed a microtubule-interacting protein that also induces G 2 /M arrest. However, Song et al. (2004) did not observe RASSF1C interactions with microtubules and we do not know the reason for the difference; future studies are expected to provide further insight into this issue.
While our current findings and those reported by others (Liu et al., 2003; Song et al., 2004) support the notion that RASSF1A regulates mitotic progression, it remains unclear that whether altered microtubule stabilization or the interactions with Cdc20 by RASS-F1A is the primary cause of mitotic arrest. In fact, previous studies have demonstrated that disruption of microtubule dynamics either by microtubule-stabilizing/ destabilizing agents, such as taxol, vinblastine and nocodozol (reviewed in Bhalla, 2003) ; or by microtubule-destabilizing protein, such as stathmin (also called oncoprotein 18; reviewed in Walczak, 2000) , affects cell cycle progression at M phase. Future studies are needed to elucidate whether RASSF1A exerts its regulatory effect during mitotic progression via one or both of these mechanisms, and such studies will provide important insights to better understand how this novel tumor suppressor mediates its biological effects.
Materials and methods

Antibodies and reagents
Anti-GFP antibody was purchased from Boehringer Mannheim (Indianapolis, IN, USA); a-tubulin antibody was purchased from Sigma Chemicals (St Louis, MO, USA); anti-Myc antibody was purchased from Santa Cruze Biotechnology, Inc. (Santa Cruze, CA, USA); the rhodamineconjugated anti-mouse IgG secondary antibody was from Pierce (Rockford, IL, USA). Taxol and nocodazole were purchased from Sigma Chemicals (St Louis, MO, USA).
Cell culture conditions
MCF-7, the human breast carcinoma cells, HCT116, the human colon carcinoma cells, A549, the human lung carcinoma cells, 293T, the human embryonic kidney cells and mouse embryonic fibroblasts (MEF) were regularly maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum. NIH3T3, the mouse fibroblasts were maintained in DMEM supplemented with 10% calf serum. Cells growing in tissue culture dishes or Lab-Tek II chamber slides were transfected with LipofectAmine 2000 (Invitrogene, Carlsbad, CA, USA) or Superfect (Qiagen Inc., Valencia, CA, USA) reagents according to the protocols provided by the manufacturers.
Plasmid constructs
To generate GFP-tagged RASSF1A or RASSF1C, the fulllength RASSF1A or RASSF1C cDNAs were subcloned into a pEGFPc1 mammalian expression vector (BD Biosciences Clontech, Palo Alto, CA, USA) such that the open reading frame (ORF) of RASSF1A or RASSF1C is in-frame with the ORF of GFP, and the GFP is present at the N-terminal end of RASSF1A or RASSF1C. To generate the Myc-tagged RASSF1A fusion construct, the ORF of RASSF1A was subcloned in-frame downstream of a Myc-tag sequence and the fused cDNA was inserted at the multiple cloning site of pCEP4 mammalian expression vector (Invitrogen, Carlsbad, CA, USA), which contains a hygromycin selection marker. All vectors were sequenced to confirm the RASSF1A sequence. The GFP-tagged RASSF1A deletion constructs were generated by using Quick Change Site Directed Mutagenesis XL kit (Stratagene, La Jolla, CA, USA). All vectors were sequenced to confirm the correct RASSF1A sequence.
Generation of RASSF1A antibodies and detection of RASSF1A protein
To detect endogenous RASSF1A protein, two anti-human RASSF1A-specific antibodies were generated (Bethyl Laboratories, Montgomery, TX, USA). We used two overlapping polypeptides, CGEPELIELRELAPAGRAGKG and AGKGRTRLERANALRIA RGT, representing the N-terminal RASSF1A sequences specific to the RASSF1A isoform as antigens to immunize animals, and two different polyclonal antibodies were raised. These antibodies were subsequently used to detect the endogenous RASSF1A's expression by Western blot analysis as well as its interaction with microtubules by co-immunoprecipitation. Western blot analyses were performed as previously described (Rong et al., 2002) . To detect the endogenously expressed RASSF1A protein, cells grown in 100-mm plates were lysed in a lysis buffer as previously described (Rong et al., 2002) and subjected to Western blot analysis. To detect the expression of Myc-tagged or GFP-tagged RASSF1A protein, the control pCEP4 vector and pCEP4 Myc-tagged RASSF1A expression vector or the GFP-tagged RASSF1A and the GFP alone control vector were used in transfections. The 293T cells were transiently transfected with indicated expression vectors and 24 h after transfection, cells were lysed and the cell lysates were subjected to Western blot analysis by standard methods using either anti-GFP or anti-Myc antibodies.
Microtubule cosedimentation assay
The microtubule cosedimentation assay was performed to detect RASSF1A and microtubule interactions in vivo. The microtubule cosedimentation assay was performed as previously described (Goedert et al., 1996; Goode et al., 2000; Reese and Haimo, 2000; Walenta et al., 2001 ) with modifications. Briefly, 293T cells were transfected either with GFPalone or GFP-RASSF1A construct. At 24 h after transfection, cells were lysed with lysis buffer (80 mM Pipes, pH 7.0, 1 mM EGTA, 1 mM MgCl 2 ) and total cell lysates were incubated with taxol (80 mM) in the presence of GTP (2 mM). After incubation, the samples were spun through a cushion buffer containing 40% glycerol at 100 000 g for 45 min as described (Walenta et al., 2001) . Supernatant (S) and pellet (P) were then collected separately and were immunoblotted with anti-GFP or anti-atubulin antibodies.
RT-PCR analysis
The expression of RASSF1A mRNA in different human cancer cell lines was analysed by the RT-PCR method using the SuperScript First Strand Synthesis System (Life Technologies, Inc.) as per the manufacturer's protocol. Briefly, 1 mg of total RNA was used in each RT reaction. For PCR amplification, 1/10 of the cDNA sample from each RT reaction was mixed with 1 U of Taq DNA polymerase (Fisher Scientific Company, Suwanee, GA, USA), 200 mM deoxynucleotide triphosphate, 1.5 mM MgCl 2 and 20 pmol of the following primers in a 50-ml total volume. RASSF1A-specific sense primer: 5 0 -GGCGTCGTGCGCAAAGGCC-3 0 . RASS-F1A antisense primer: 5 0 -GGGTGGCTTCTTGCTGGAGG G-3 0 (Burbee et al., 2001) . For amplification of RASSF1A PCR products, we used the following conditions: 951C for 2 min and followed by two cycles of 941C for 40 s, 691C for 40 s, and 721C for 40 s. For first few cycles, the annealing temperature was decreased 11 for every two cycles until it reached 611C. The reaction was continued at 941C for 40 s, 611C for 40 s, and 721C for 45 s for total of 24 cycles. Aliquots of 12 ml of each PCR product were analysed by 1.5% agarose gel electrophoresis and ethidium bromide staining. PCR reactions to detect b-actin was performed using duplicate cDNA aliquots from each RT reaction using the same conditions as we have previously described .
Immunostaining
Immunostaining to detect a-tubulin was performed as previously described with modifications (Szalay et al., 2001) . Briefly, cells growing on Lab-tek slides were transiently transfected with expression vector carrying GFP cDNA or GFP-RASSF1A fusion construct. Approximately 24 h after transfection, cells were fixed with 1% paraformaldehyde for 1 h followed by cold methanol at À201C for 10 min. Cells were labeled with a-tubulin primary antibody (1 : 500, Sigma Chemicals, St Louis, MO, USA), followed by a rhodamineconjugated secondary antibody. DNA was counterstained with DAPI nuclear dye as we have previously described . Slides were examined under an Olympus fluorescent microscope using appropriate filters.
Immunoprecipitation
The interaction of the endogenous RASSF1A protein and microtubule was detected by co-immunoprecipitation (IP) of RASSF1A and a-tubulin proteins. Immunoprecipitation with magnetic protein G beads (Dynal Biotech, Lake Success, NY, USA; also referenced in Erimann and Jackson, 2002) was performed according to the manufacture's instructions. Briefly, MEF or 293T cells were lysed in PEM buffer (Walenta et al., 2001 ) and 1 mg of total cell lysates was incubated with taxol (80 mM) and GTP to stabilize the microtubules. After 40 mins incubation, cell lysates were incubated and rotated in the presence or absence of mouse monoclonal anti-a tubulin antibody (25 mg) or equal amount of control mouse IgG overnight at 41C. Then, 100 ml of Dynal protein G magnetic beads were mixed with each sample and incubated under rotation at room temperature for 40 min. The protein-bound beads were collected by magnet and washed three times with PEM buffer containing 150 mM NaCl. The protein complexes immobilized on the beads were eluted by 1 Â Western loading buffer and subjected to Western blotting using anti-RASSF1A antibodies.
Colony formation assay
The MCF-7, Hela and HCT116 human breast, cervical and colon cancer cells, respectively, were transfected with equimolar concentrations of control empty vector or the Myc-tagged RASSF1A expression vector (both of these vectors contain a hygromycin-resistant marker) with Lipofectamine 2000 transfection reagents (GIBCO-BRL) as per the manufacture's protocol. Cells were subsequently selected in hygromycin (150-250 g/ml) for 14-20 days and stained with crystal violet.
Flow cytometry
MCF-7 and 293T cells, seeded in 100 mm plates at 40-50% confluency, were transfected with 10 mg of plasmids expressing either GFP-alone, GFP-RASSF1A or GFP-RASSF1C expression constructs. At 24 , 48 and 72 h after transfection, cells were trypsinized, washed and fixed with 1% paraformaldehyde for 1 h. Cells were then washed in 1 Â PBS, incubated with 70% ethanol, treated with RNase followed by staining with propidium iodide. The cell cycle phase distributions were determined by analysing DNA content of the GFP (green fluorescent protein)-expressing cells by flow cytometry.
